ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – GERN

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Geron Corporation securities between February 28, 2024, and February 25, 2025, about the May 12, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Geron securities during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5] - The lead plaintiff must file a motion with the court by May 12, 2025, to represent other class members in the litigation [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3] Group 3: Case Allegations - The lawsuit alleges that Geron Corporation made false and misleading statements regarding the launch of its drug RYTELO, claiming that various factors would impair its profitability [4] - Specific claims include a lack of awareness among healthcare providers, the requirement for weekly monitoring, and competition affecting Geron's ability to meet market needs [4] - As a result of these misrepresentations, Geron's business and financial prospects were overstated, leading to investor damages when the truth was revealed [4]